Nyxoah (NYXH) Stock Price, News & Analysis

Company Overview

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key Stats

• Today's Range: $6.90 to $7.60
• 50-Day Range: $7.12 to $8.28
• 52-Week Range: $5.55 to $11.87
• Volume: 60,727 shs
• Average Volume: 43,328 shs
• Market Capitalization: $248.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.50
• Consensus Rating: Buy

Nyxoah Stock Analysis - MarketRank™

Nyxoah scored higher than 52% of companies evaluated by MarketBeat, and ranked 489th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nyxoah has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nyxoah has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nyxoah are expected to grow in the coming year, from ($1.91) to ($1.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nyxoah is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nyxoah is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nyxoah has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.72% of the float of Nyxoah has been sold short.

Short Interest Ratio / Days to Cover

Nyxoah has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nyxoah has recently decreased by 1.28%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nyxoah does not currently pay a dividend.

Dividend Growth

Nyxoah does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.72% of the float of Nyxoah has been sold short.

Short Interest Ratio / Days to Cover

Nyxoah has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nyxoah has recently decreased by 1.28%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.46

News Sentiment

Nyxoah has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Nyxoah this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nyxoah insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.11% of the stock of Nyxoah is held by insiders. A high percentage of insider ownership can be a sign of company health.

NYXH Stock Analysis - Frequently Asked Questions

How have NYXH shares performed this year?

Nyxoah's stock was trading at $8.00 at the start of the year. Since then, NYXH stock has decreased by 8.8% and is now trading at $7.30.

How were Nyxoah's earnings last quarter?

Nyxoah SA (NASDAQ:NYXH) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.14. The company earned $1.12 million during the quarter, compared to analysts' expectations of $1.64 million. Nyxoah had a negative trailing twelve-month return on equity of 63.37% and a negative net margin of 1,571.39%.
Read the conference call transcript.

When did Nyxoah IPO?

Nyxoah (NYXH) raised $83 million in an IPO on Friday, July 2nd 2021. The company issued 2,760,000 shares at a price of $30.00 per share.

How do I buy shares of Nyxoah?

Shares of NYXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nyxoah own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nyxoah investors own include PayPal (PYPL), Confluent (CFLT), Datadog (DDOG), Baidu (BIDU), Arcadia Biosciences (RKDA), SEA (SE) and ZoomInfo Technologies (ZI).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 8/03/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NYXH
• CIK: 1857190
• Web: www.nyxoah.com
• Phone: 321-022-2355
• Fax: 321-045-9075
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Nyxoah: $14.50
• High Price Target: $16.00
• Low Price Target: $13.00
• Potential Upside/Downside: +98.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.10 million
• Net Margins: -1,571.39%
• Pretax Margin: -1,529.93%
• Return on Equity: -63.37%
• Return on Assets: -46.67%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 3.59
• Quick Ratio: 3.35

Sales & Book Value

• Annual Sales: $4.89 million
• Price / Sales: 50.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.60 per share
• Price / Book: 2.03

Miscellaneous

• Outstanding Shares: 34,060,000
• Free Float: 28,232,000
• Market Cap: $248.64 million
• Optionable: Not Optionable
• Beta: 1.61